基于Multiomics策略的肥胖生物标志物的发现,用于精准医学
Zu-Wen Ye1, Qi-Yue Yang2, Wen-Ting Xu1
1Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, China.
International journal of obesity (2005)
|October 14, 2025
概括
这篇评论探讨了肥胖问题.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 肥胖研究的研究.
- 发现生物标志物的发现.
背景情况:
- 肥胖是一种复杂的代谢障碍,具有多种原因和并发症.
- 管理肥胖症是具有挑战性的,因为它的异质性.
- 多组学技术为肥胖的分子基础提供了新的见解.
研究的目的:
- 审查导致肥胖的因素.
- 探索多组学方法来识别肥胖生物标志物.
- 讨论确定生物标志物的临床应用和局限性.
主要方法:
- 综述多组学数据 (表观遗传学,转录组学,蛋白质组学,代谢组学,肠道微生物组).
- 在多学科研究中分析数据整合方法.
- 确定肥胖生物标志物的临床适用性评估.
主要成果:
- 多组学研究揭示了肥胖的潜在病因机制.
- 在生物标志物识别方面,综合性多种经济学战略正在取得进展.
- 已经确定了许多有前途的肥胖生物标志物,但需要进一步验证.
结论:
- 多组学方法为精确的肥胖治疗提供了新的方向.
- 针对性干预,如表观遗传修饰或微生物组调制,显示出潜在的潜力.
- 纵向和人口特异性研究对于推进肥胖管理至关重要.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166


